Tyra Biosciences, Inc.
No enriched coverage for $TYRA in the last 7 days.
No SEC Form 4 filings for $TYRA in the last 30 days.
See all $TYRA insider activity →Raymond James analysts identified top healthcare stocks, including Dyne Therapeutics (DYNE-251 data expected 4Q25), Ocular Therapeutix (SOL-R enrollment visibility improving), Trevi Therapeutics (Phase 2b readout in 1H25), and Tyra Biosciences (Phase 2 data in 2026). All are rated Strong Buy or Outperform.
Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.
William Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
Recent TYRA coverage spans financial news, technology and corporate actions.
Analyst ranking may lift the stock ahead of multiple 2026 trial readouts.
Positive Phase 2 results are likely to lift TYRA stock as investors price in a promising lead asset.
Potential slight downside.
Analyst upgrade may lift the stock toward the $29 target.
Positive early efficacy may drive near-term price appreciation and set up Phase 3 momentum.
AlphAI scores every news story that mentions TYRA with an AI model for sentiment and relevance, and aggregates insider trades from Tyra Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Raymond James analysts identified top healthcare stocks, including Dyne Therapeutics (DYNE-251 data expected 4Q25), Ocular Therapeutix (SOL-R enrollment visibility improving), Trevi Therapeutics (Phase 2b readout in 1H25), and Tyra Biosciences (Phase 2 data in 2026). All are rated Strong Buy or Outperform.
3 min readRaymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.
2 min readWilliam Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
2 min readHC Wainwright & Co. kept a Buy rating on Tyra Biosciences (TYRA) with a $29 price target, suggesting a 13.1% upside from the Sep 21 close. The firm highlights Tyra's pipeline and SNAP platform as strengths.
1 min readTyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.
2 min readTyra priced an offering of 9.08M common shares at $22.03 each and 9.08M pre-funded warrants at $22.029 each, expected to raise $400M. Underwriters bought at $20.7082 per unit. Proceeds will support drug development and corporate purposes, according to the company.
1 min readTyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.
3 min readElmet Group (ELMT) shares surged 50.6% to $24.39 after announcing plans to use a $450M DoD investment to boost tungsten supply. Other stocks gaining include Rum Group (RUM) +15%, Tyra Biosciences (TYRA) +14.5%, and Roblox (RBLX) +8.7% after price target raises.
2 min readTyra Biosciences (TYRA) stock rose 9.8% after announcing a $400M public offering at $22.03 per share, with proceeds funding clinical programs. The offering was led by RA Capital and major banks, following positive Phase 2 trial results. The company aims to advance its dabogratinib 3x3 strategy, targeting specific cancers and achondroplasia.
2 min readVerjee Rehan purchased 972 shares of Tyra Biosciences, Inc. (TYRA) at $20.58 on 2026-09-09.
1 min read
